Silexion Therapeutics Corp 8-K

What Happened

• On May 14, 2026, Silexion Therapeutics Corp. (SLXN) filed a Form 8‑K under Item 7.01 (Regulation FD Disclosure) to furnish a press release titled “Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS‑Driven Pancreatic Cancer.” The press release is furnished as Exhibit 99.1 and is incorporated by reference in the filing.
• The company reported positive preliminary immunotherapy findings for its candidate SIL204 in KRAS‑driven pancreatic cancer. The 8‑K does not include additional clinical data, financial results, or details beyond the press release.

Key Details

• Filing date: May 14, 2026 (Form 8‑K filed to disclose the press release).
• Announcement: Positive preliminary immunotherapy findings for SIL204 in KRAS‑driven pancreatic cancer.
• Disclosure format: Press release furnished as Exhibit 99.1 to the Form 8‑K (Item 7.01 Regulation FD Disclosure).
• No additional financial statements or clinical data were included in the Form 8‑K beyond the furnished press release.

Why It Matters

• This filing is an official, Reg FD disclosure that Silexion publicly released positive early results for SIL204; investors should view it as a confirmed update on the company’s clinical program.
• While positive preliminary findings can be a catalyst for investor interest, the 8‑K does not provide detailed data, timelines, or regulatory next steps—investors should look for subsequent releases or clinical reports for substantive metrics that could affect valuation or partnership prospects.